AnHeart Therapeutics, a biopharmaceutical group company committed to developing novel precision oncology therapies, closed a $61m in Series B financing.
The round was led by new investor Octagon Capital, with participation from Innovent Biologics, Cenova, Laurion Capital, and Sage Partners.
The company, which has raised a total of $100m in gross proceeds from private financings since its founding in December 2018, intends to use the funds to:
- advance the clinical development of its lead asset, taletrectinib, a next-generation ROS1 inhibitor currently in Phase 2 trials in non-small cell lung cancer (NSCLC),
- continue to expand its pipeline of precision next-generation oncology therapeutics, and
- grow its team of scientists and researchers.
Led by Junyuan (Jerry) Wang, Ph.D., Co-Founder and Chief Executive Officer, and Lihua Zheng, J.D., Ph.D., Co-Founder and Chief Business Officer, AnHeart Therapeutics is a clinical-stage global biopharmaceutical group company developing a broad pipeline of novel or next-generation precision oncology therapeutics with high unmet medical needs. Its lead asset, taletrectinib, is a next-generation ROS1 and NTRK inhibitor currently in Phase 2 trials for the first-line and second-line ROS1 fusion positive non-small cell lung cancer (NSCLC) and NTRK fusion positive solid tumors. The company’s pipeline also includes AB-218, a mIDH1 inhibitor in Phase 2 trials for lower grade glioma, cholangiocarcinoma, AML and other tumors and AB-329, an AXL inhibitor in Phase 1 studies to be used in combination with checkpoint inhibitor or chemotherapies in NSCLC, ovarian cancer and breast cancers.
The company is a a Cayman Islands entity operating from offices in the US and China.